Neuroendocrine Tumor Treatment Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis 2018 - 2025 Incidence and prevalence of neuroendocrine tumor is steadily rising, mainly due Multiple endocrine neoplasia type 1 (MEN1), Multiple endocrine neoplasia type 2 (MEN2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL) and Tuberous sclerosis complex (TSC) disease in the U.S. Moreover, based on a study published in the JAMA Oncology Journal, survival rate for all neuroendocrine tumor treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumor treatment and pancreatic neuroendocrine tumor treatment. This is mainly attributed to improved outcomes of availability of better therapies and early diagnosis. Introduction of new therapies and extended indications for approved drugs would benefit the growth of neuroendocrine tumor treatment market in North America and in turn is expected to significantly fuel growth of the global market. U.S. is the largest market for NET, in terms of revenue. No specific data is available regarding incidence of neuroendocrine tumors in Canada. However, according to the Canadian Cancer Society, 315 people in Canada were diagnosed with endocrine cancers in 2012 and the rate is increasing with early diagnosis and stage migration. Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/129 North America neuroendocrine tumor treatment market is expected to dominate the global gastrointestinal NET segment throughout the forecast period. According to Coherent Market Insights analysis, various national universities and small scale pharma-company work on developing various NET drugs and modify clinical approach to treat neuroendocrine tumors. This gives pharma and biotech companies a major opportunity to market their products in the U.S. The global neuroendocrine tumor treatment market was valued at US$ 1,197.3 million in 2015 and is expected to witness a CAGR of 10.5% during the forecast period (2017 – 2025) Innovate drug in pharmaceutical company product pipeline to boost the Neuroendocrine Tumor Treatment Market There are various medical treatment to treat cancer, and targeted therapy is one of the most preferred to treat neuroendocrine tumor treatment. Targeted therapy is a futuristic and highly effective approach for treating cancers and hence, targeted NET therapies are projected to gain significant demand in the near future. Though somatostatins are effective in treating some types of pituitary tumors, regulatory approval for NET is expected to further encourage its research as a combination therapy with targeted drugs. Report includes chapters which deeply display the following deliverable about industry : • Neuroendocrine Tumor Treatment Market Research Objective and Assumption • Neuroendocrine Tumor Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Neuroendocrine Tumor Treatment Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Neuroendocrine Tumor Treatment Market, By Regions • Neuroendocrine Tumor Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Neuroendocrine Tumor Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Neuroendocrine Tumor Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Neuroendocrine Tumor Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Key Players Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc.and Exelixis, Inc. Detailed Segmentation: Global Neuroendocrine Tumor Treatment Market, By Drug: • Everolimus • Sunitinib Malate • Lu-Dotate • Lanreotide • Octreotide Global Neuroendocrine Tumor Treatment Market, By Indication: • Gastrointestinal NET • Lung NET • Pancreatic NET • Others NET Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/marketinsight/neuroendocrine-tumors-treatment-market-129 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200, Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
The global neuroendocrine tumor treatment market was valued at US$ 1,197.3 million in 2015 and is expected to witness a CAGR of 10.5% By 2025
© Copyright 2024 Paperzz
